Hot Topics

Poll

Why is it a big mistake to link funding of R&D costs with drug prices?:

Regional Comprehensive Economic Partnership, Japan IPR proposals, October 3, 2014

Attached is a leaked version of Japan's October 3, 2014 proposals for intellectual property for the Regional Comprehensive Economic Partnership.

The Regional Comprehensive Economic Partnership (RCEP) is a proposed free trade agreement (FTA) between the ten member states of the Association of Southeast Asian Nations (ASEAN) (Brunei, Burma (Myanmar), Cambodia, Indonesia, Laos, Malaysia, the Philippines, Singapore, Thailand, Vietnam) and the six states with which ASEAN has existing FTAs (Australia, China, India, Japan, South Korea and New Zealand).

KEI 2015 Special 301 Comments (filed February 6, 2015)

Attached are KEI's February 6 comments to USTR on the 2015 Special 301.

Our 7 page submission begins with this:

KEI comments on India IP strategy

Attached are KEI's January 30, 2015 comments on the India IP Policy.

http://keionline.org/sites/default/files/KEI_30Jan2015_Comments_India_IPR_Policy.pdf

This is how the comments begin:

Knowledge Ecology International (KEI) has reviewed the document entitled “National IPR Policy” prepared by the IPR Think Tank. The document is surprisingly lacking in several key areas. In particular:

On World Cancer Day, do we celebrate the approval of Pfizer's $118,200 drug Ibrance?

Today, on World Cancer Day, there has been many great announcements and celebrations.

The FDA approved Pfizer's new drug Ibrance (INN: palbociclib) for the treatment of metastatic (advanced) breast cancer to be used in combination with letrozole based on a 165 person trial at UCLA's cancer center. (FDA press release here, ABC story here.)

WTO TRIPS Council (February 2015): Norway and the United States bring gender mainstreaming to the fore-Women and Innovation

The first session of the 2015 World Trade Organization's TRIPS Council takes place from 24 February 2015 to 25 February 2015. Like clockwork, the United States has tabled the inclusion of an additional item on Intellectual Property and Innovation. This marks the 8th time since November 2012 that the United States has submitted the inclusion of an additional agenda item to the TRIPS Council relating to intellectual property or innovation.

UACT letter to Professor DiMasi, asking for answer to five questions about new R&D cost study

February 4, 2015 is World Cancer Day. The rapidly increasing cost of cancer drugs should be broadly discussed. The Union for Affordable Cancer Treatment (UACT), a union of people affected by cancer (http://cancerunion.org/) is asking the author and co-author of the "Tufts Cost Study," --a not-yet-released "study" used to justify high prices of drugs without providing data-- to address the following questions:

EB 136 Draft decision passed on the Global Strategy and Plan of Action on Public Health, Innovation, and Intellectual Property

On Tuesday February 3, 2015, the final day of the 136th WHO Executive Board meeting, the EB passed a draft decision on the Global Strategy and Plan of Action on Public Health, Innovation, and Intellectual Property (GSPoA). The draft decision recommends to the WHA that the GSPOA be extended until 2022.

EB 136 Friday, January 30th: Discussion of Consultative Expert Working Group on Research Development-Financing and Coordination

Another matter considered during the Friday, January 30th session of the WHO Executive Board was the "Follow-up of the report on the Consultative Expert Working Group on Research Development-Financing and Coordination." In addition to the general report on the CEWG, the EB also considered the Director General's report on the CEWG "Health research and development demonstration projects."

EB 136 Friday, January 30th: Global Strategy and Plan of Action on Public Health, Innovation, and Intellectual Property

On Friday, January 30th, the WHO Executive Board discussed the Global Strategy and Plan of Action on Public Health, Innovation, and Intellectual Property (GSPA). The discussion covered several documents in relation to the GSPoA, including:

EB 136 Tuesday January 28: WHO Engagement with Non-state Actors; US issues apology to the African Group

During Tuesday's session of the WHO Executive Board, the board considered a proposal from Argentina on the table for a "Framework of Engagement with Non-state Actors." Many states, both Board members and non-Executive Board member states, contributed to the discussion, citing the issue as a critical reform issue for the WHO. While a number of states took issue with some of the specifics of the draft proposal, for example that at current time all types of non-state actors were lumped together (i.e.

Argentina, Brazil, India and South Africa- Draft decision to extend mandate of Global Strategy and Plan of Action till 2022

On Tuesday, 27 January 2015, Argentina, Brazil, India and South Africa tabled a draft decision to extend the mandate of the Global strategy and plan of action and public health, innovation and intellectual property (EB136/CONF.7) until 2022. We expect that this draft decision will be discussed on Thursday, 29 January 2015 under agenda item 10.5, Global strategy and plan of action on public health, innovation and intellectual property.

EB 136 WHO Special Session: Unanimous Ebola Resolution [finally reached on Sunday]

On Sunday January 25, 2015, the WHO Executive Board unanimously approved the resolution, "Ebola: Ending the current outbreak, strengthening global preparedness, and ensuring WHO capacity to prepare for and respond to future large-scale outbreaks and emergencies with health consequences." Though unanimous in the end, negotiations for the resolution took 4 days, the Friday session lasting until 5:45am on Saturday morning.

WTO TRIPS Council (October 2014): Bangladesh statement (on behalf of LDCs)- Extension of the 2016 transition period

At the WTO TRIPS Council in October 2014, Bangladesh, on behalf of the LDC Group, delivered the following intervention on "Extension of the Transition Period Under Article 66.1 of the TRIPS Agreement for Least-Developed Country Members for Certain Obligations with Respect to Pharmaceutical Products." The current transition period incorporate two WTO decisions, TRIPS Council decision, IP/C/25 (Extension of the Transition Period under Article 66.1 of the TRIPS Agreement for Least-Developed Country Members for Certain Obligat

EB136: WHO outlines contours of a Pooled Fund for Global Health Research and Development

In May 2014, the World Health Organization's member countries passed decision 67(15) instructing WHO Director-General Margaret Chan to explore, with TDR, the possibility of hosting a pooled funding mechanism for R&D.

Syndicate content